215 related articles for article (PubMed ID: 24488444)
1. Non-deep-seated primary CNS lymphoma: therapeutic responses and a molecular signature.
Iwadate Y; Suganami A; Ikegami S; Shinozaki N; Matsutani T; Tamura Y; Saeki N; Yamanaka R
J Neurooncol; 2014 Apr; 117(2):261-8. PubMed ID: 24488444
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Key Factors Associated with Response to Salvage High-Dose Methotrexate Rechallenge in Primary Central Nervous System Lymphoma with First Relapse.
Du P; Chen H; Shen L; Liu X; Wu X; Chen L; Cao A; Geng D
Curr Oncol; 2022 Sep; 29(9):6642-6656. PubMed ID: 36135091
[TBL] [Abstract][Full Text] [Related]
3. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
4. Comparing the Efficacy of DeVIC Therapy and High-dose Methotrexate Monotherapy with Whole-brain Radiation Therapy for Newly-diagnosed Primary Central Nervous System Lymphoma: A Single Institution Study.
Chalise L; Motomura K; Ohka F; Hirano M; Hara M; Nishimura Y; Natsume A; Wakabayashi T
Anticancer Res; 2017 Sep; 37(9):5215-5223. PubMed ID: 28870957
[TBL] [Abstract][Full Text] [Related]
5. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
[TBL] [Abstract][Full Text] [Related]
6. Long-term remission of primary central nervous system lymphoma by intensified methotrexate chemotherapy.
Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T; Fukushima T
J Neurooncol; 2003 May; 63(1):87-95. PubMed ID: 12814260
[TBL] [Abstract][Full Text] [Related]
7. Continuous intrathecal injection therapy of methotrexate is a therapeutic option in primary CNS lymphoma.
Otani R; Yamada R; Kushihara Y; Inazuka M; Shinoura N
J Clin Neurosci; 2019 Nov; 69():26-30. PubMed ID: 31466902
[TBL] [Abstract][Full Text] [Related]
8. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma.
Holdhoff M; Ambady P; Abdelaziz A; Sarai G; Bonekamp D; Blakeley J; Grossman SA; Ye X
Neurology; 2014 Jul; 83(3):235-9. PubMed ID: 24928128
[TBL] [Abstract][Full Text] [Related]
9. High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials.
Yu J; Du H; Ye X; Zhang L; Xiao H
Sci Rep; 2021 Jan; 11(1):2125. PubMed ID: 33483528
[TBL] [Abstract][Full Text] [Related]
10. High-dose methotrexate monotherapy for newly diagnosed primary central nervous system lymphoma: 15-year multicenter experience.
Yoon WS; Park JS; Kim YI; Chung DS; Jeun SS; Hong YK; Yang SH
Asia Pac J Clin Oncol; 2021 Feb; 17(1):123-130. PubMed ID: 32978898
[TBL] [Abstract][Full Text] [Related]
11. GSEA-assisted gene signatures valid for combinations of prognostic markers in PCNSL.
Takashima Y; Hamano M; Fukai J; Iwadate Y; Kajiwara K; Kobayashi T; Hondoh H; Yamanaka R
Sci Rep; 2020 May; 10(1):8435. PubMed ID: 32439996
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Evaluation of Combination Treatment of Single Agent HD-MTX Chemotherapy up to Three Cycles and Moderate Dose Whole Brain Irradiation for Primary CNS Lymphoma.
Kobayashi H; Yamaguchi S; Motegi H; Kaneko S; Endou S; Onimaru R; Terasaka S; Houkin K
J Chemother; 2019 Feb; 31(1):35-41. PubMed ID: 30773132
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival.
Martinez-Calle N; Poynton E; Alchawaf A; Kassam S; Horan M; Rafferty M; Kelsey P; Scott G; Culligan DJ; Buckley H; Lim YJ; Ngu L; McCulloch R; Rowntree C; Wright J; McKay P; Fourali S; Eyre TA; Smith J; Osborne W; Yallop D; Linton K; Fox CP; Cwynarski K
Br J Haematol; 2020 Aug; 190(3):394-404. PubMed ID: 32232989
[TBL] [Abstract][Full Text] [Related]
14. High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study.
Illerhaus G; Marks R; Müller F; Ihorst G; Feuerhake F; Deckert M; Ostertag C; Finke J
Ann Oncol; 2009 Feb; 20(2):319-25. PubMed ID: 18953065
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of completion of initial high-dose methotrexate therapy on primary central nervous system lymphoma: a single institution experience.
Makino K; Nakamura H; Hide T; Kuroda J; Yano S; Kuratsu J
Int J Clin Oncol; 2015 Feb; 20(1):29-34. PubMed ID: 24722885
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of temozolomide plus concurrent whole-brain radiation followed by TNV regimen as adjuvant therapy for patients with newly diagnosed primary CNS lymphoma.
Wang Y; Liu B; Xu D; Zhao H; Zhu Y; Xu J; Tao R
Neurol India; 2013; 61(3):260-4. PubMed ID: 23860145
[TBL] [Abstract][Full Text] [Related]
17. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
[TBL] [Abstract][Full Text] [Related]
18. High-dose cytarabine salvage therapy for recurrent primary CNS lymphoma.
Chamberlain MC
J Neurooncol; 2016 Feb; 126(3):545-50. PubMed ID: 26563190
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of polyglutamylation in primary central nervous system lymphoma.
Shinojima N; Fujimoto K; Makino K; Todaka K; Yamada K; Mikami Y; Oda K; Nakamura K; Jono H; Kuratsu JI; Nakamura H; Yano S; Mukasa A
Acta Neuropathol Commun; 2018 Feb; 6(1):15. PubMed ID: 29475458
[TBL] [Abstract][Full Text] [Related]
20. Continued-Maintenance Therapy with High-dose Methotrexate Improves Overall Survival of Patients with Primary Central Nervous System Lymphoma.
Nakajima K; Mizobuchi Y; Fujihara T; Azumi M; Takagi Y
J Med Invest; 2021; 68(3.4):286-291. PubMed ID: 34759146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]